61 completed, 26 recruiting, 18 unknown, 14 terminated. 70 Phase 2, 51 Phase 1, 15 Phase 3, 7 Not applicable, 1 Early Phase 1.
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy Allogeneic Stem Cell Transplant - MDS, Myelodysplastic Syndrome MDS | Phase 2 | Not yet recruiting | Ronald Paquette | 20 | 2026-12-01 | 2026-10-28 |
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation TSC-101, Control - AML, MDS | Phase 3 | Active not recruiting | TScan Therapeutics, Inc. | 310 | 2026-06-18 | 2026-10-05 |
| SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped mBUCY, mBUCY conditioning Regimen Group - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 180 | 2026-06-01 | 2026-06-10 |
| SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 160 | 2026-06-01 | 2026-05-01 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| Quality of Life-Guided Transfusion in Refractory MDS or AML Red blood cell transfusions based on EQ-5D-5L questionnaire - MDS, AML, Adult | Not applicable | Recruiting | Centre Hospitalier Universitaire de Nice | 52 | 2026-02-09 | 2026-02-12 |
| A Long Term Follow-up Study of TScan TCR-T Products Observational - AML, ALL | Recruiting | TScan Therapeutics, Inc. | 1000 | 2025-09-09 | 2025-09-10 | |
| QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) Allogeneic TCR-enhanced γδ T cell(QH101), Fludarabine (FLU), Cyclophosphamide (CTX) - MDS, AML | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 9 | 2025-08-15 | 2025-08-20 |
| Reduced Intensity Conditioning for MDS Fludarabine; melphalan; busulfan - MDS | Phase 2 | Not yet recruiting | Ruijin Hospital | 45 | 2025-08-01 | 2025-07-25 |
| Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation Ivosidenib 250 MG (milligram) - AML, MDS | Phase 2 | Recruiting | Technische Universität Dresden | 76 | 2025-06-17 | 2026-08-26 |
| Safety of MT-401-OTS in Patients With Relapsed AML or MDS MT-401-OTS - Acute Myeloid Leukemia, in Relapse, MDS | Phase 1 | Recruiting | Marker Therapeutics, Inc. | 40 | 2025-06-16 | 2025-12-16 |
| Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation Decitabine, Sorafenib (BAY-43-9006)，giritinib, Avastinib - AML, MDS | Phase 2 / Phase 3 | Recruiting | Ruijin Hospital | 126 | 2025-06-10 | 2025-05-18 |
| A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) Decitabine - MDS | Phase 1 | Recruiting | Treebough Therapies | 20 | 2025-06-03 | 2026-01-15 |
| Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients PERIBLOOD-MDS - Cytopenia, MDS | Recruiting | Weizmann Institute of Science | 1500 | 2025-06-01 | 2026-03-25 | |
| Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) - Leukemia, MDS | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 24 | 2025-05-03 | 2026-08-05 |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine - AML, Adult, MDS | Phase 1 | Recruiting | Stelexis BioSciences | 105 | 2025-04-28 | 2026-10-20 |
| A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies CG009301 for Injection - Leukemia, AML | Phase 1 | Recruiting | Cullgen (Shanghai),Inc | 45 | 2025-04-17 | 2026-01-16 |
| OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study OURA Ring - MDS, Myelodysplastic Syndromes | Recruiting | Sunnybrook Health Sciences Centre | 60 | 2025-03-20 | 2025-07-08 | |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
Showing 20 of 142. Sign in to see all of them.
Leukemia, Myeloid, Acute (40) · Myelodysplastic Syndromes (40) · Leukemia (19) · Lymphoma (11) · Multiple Myeloma (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Hematologic Neoplasms (9) · Hodgkin Disease (9) · Anemia, Refractory, with Excess of Blasts (8) · Leukemia, Myelomonocytic, Chronic (8) · Lymphoma, Non-Hodgkin (8) · Myeloproliferative Disorders (8) · Recurrence (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Anemia (4)
Hemic and Lymphatic Diseases (92) · Hematologic Diseases (89) · Neoplasms (64) · Neoplasms by Histologic Type (63) · Bone Marrow Diseases (55) · Leukemia, Myeloid (45) · Leukemia (40) · Immune System Diseases (32) · Immunoproliferative Disorders (27) · Lymphoproliferative Disorders (27) · Lymphatic Diseases (26) · Pathologic Processes (26) · Pathological Conditions, Signs and Symptoms (26) · Disease Attributes (24) · Chronic Disease (16)
Azacitidine (26) · Cyclophosphamide (18) · fludarabine (15) · Decitabine (12) · Busulfan (9) · Cytarabine (9) · Mycophenolic Acid (9) · fludarabine phosphate (9) · Whole-Body Irradiation (8) · venetoclax (8) · Granulocyte Colony-Stimulating Factor (7) · Antilymphocyte Serum (5) · Cyclosporine (5) · Lenalidomide (5) · Tacrolimus (5)
Groupe Francophone des Myelodysplasies (9) · Amgen (6) · Masonic Cancer Center, University of Minnesota (5) · M.D. Anderson Cancer Center (4) · Ruijin Hospital (4) · National Cancer Institute (NCI) (3) · TScan Therapeutics, Inc. (3) · The First Affiliated Hospital of Soochow University (3) · Traws Pharma, Inc. (3) · Aprea Therapeutics (2) · Astex Pharmaceuticals, Inc. (2) · DKMS gemeinnützige GmbH (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Nordic MDS Group (2) · Peking Union Medical College Hospital (2)
United States (74) · China (23) · France (18) · Germany (13) · Italy (8) · Canada (7) · Belgium (6) · Austria (5) · Spain (4) · Australia (3) · Czechia (3) · Japan (3) · Norway (3) · Sweden (3) · Denmark (2)
Gautam Borthakur, MD (3) · Steven M. Fruchtman, MD (3) · Guillermo Garcia-Manero, MD (2) · Johannes Schetelig, Prof Dr med (2) · Shrikanta Chattopadhyay, MD (2) · Adam Lamble, MD (1) · Aleksandra Filipovic, MD, PhD. (1) · Anders Erik Astrup Dahm, MD, PHD (1) · Andrew Kuykendall, MD (1) · Arnold Ganser, Prof. Dr. (1) · Arthur S Alberts, PhD (1) · Bing Han, Docter (1) · Chetan Jeurkar, DO (1)
PMID 18997171, PMID 19706886, PMID 21508125, PMID 21719884, PMID 21816832, PMID 23012326, PMID 23344397, PMID 24002496, PMID 24077845, PMID 24951467, PMID 26296954, PMID 26858124, PMID 26968357, PMID 27250349, PMID 27400247, PMID 28616874, PMID 28881839, PMID 30926081, PMID 31060979, PMID 31331399, PMID 32264726, PMID 32285126, PMID 32556286, PMID 32645016, PMID 32661295, PMID 32813874, PMID 33170934, PMID 33513373, PMID 34106753, PMID 34439266, PMID 34771451, PMID 36251401, PMID 36455187, PMID 36647781, PMID 36737440, PMID 37534514, PMID 37595058, PMID 37607457, PMID 37680953, PMID 37846845, PMID 37967471, PMID 38114624, PMID 38170583, PMID 38232336, PMID 38249329, PMID 38261970, PMID 38505288, PMID 39095502, PMID 40353947, PMID 40784355
2015 (2), 2009 (1), 2016 (1), KL2RR025006 (1), P30CA033572 (1), U10HL069294 (1), U24CA076518 (1)